OpenLB
Open Library of Bioscience

Targeting interferon-γ in hyperinflammation: opportunities and challenges.

Abstract

References

1. Kastner, D. L., Aksentijevich, I. & Goldbach-Mansky, R. Autoinflammatory disease reloaded: a clinical perspective. Cell 140, 784–790 (2010). [PMID: 20303869]
2. Martinez-Quiles, N. & Goldbach-Mansky, R. Updates on autoinflammatory diseases. Curr. Opin. Immunol. 55, 97–105 (2018). [PMID: 30453204]
3. Henderson, L. A. et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheumatol. 72, 1059–1063 (2020). [PMID: 32293098]
4. Schoenborn, J. R. & Wilson, C. B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96, 41–101 (2007). [PMID: 17981204]
5. Darwich, L. et al. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology 126, 386–393 (2009). [PMID: 18759749]
6. Zhu, J. et al. The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity 37, 660–673 (2012). [PMID: 23041064]
7. Suarez-Ramirez, J. E., Tarrio, M. L., Kim, K., Demers, D. A. & Biron, C. A. CD8 T cells in innate immune responses: using STAT4-dependent but antigen-independent pathways to gamma interferon during viral infection. mBio 5, e01978-01914 (2014). [DOI: 10.1128/mBio.01978-14]
8. Kannan, Y. et al. IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells. Blood 117, 2855–2863 (2011). [PMID: 21224476]
9. Nakanishi, K. Unique action of interleukin-18 on T cells and other immune cells. Front. Immunol. 9, 763 (2018). [PMID: 29731751]
10. de Weerd, N. A. & Nguyen, T. The interferons and their receptors — distribution and regulation. Immunol. Cell Biol. 90, 483–491 (2012). [PMID: 22410872]
11. Chistiakov, D. A., Myasoedova, V. A., Revin, V. V., Orekhov, A. N. & Bobryshev, Y. V. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology 223, 101–111 (2018). [PMID: 29032836]
12. Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014). [PMID: 24669294]
13. Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787–795 (2012). [PMID: 22378047]
14. Wu, C. et al. IFN-γ primes macrophage activation by increasing phosphatase and tensin homolog via downregulation of miR-3473b. J. Immunol. 193, 3036–3044 (2014). [PMID: 25092892]
15. Asano, M., Nakane, A. & Minagawa, T. Endogenous gamma interferon is essential in granuloma formation induced by glycolipid-containing mycolic acid in mice. Infect. Immun. 61, 2872–2878 (1993). [PMID: 8514390]
16. Jaczewska, J. et al. TNF-α and IFN-γ promote lymphocyte adhesion to endothelial junctional regions facilitating transendothelial migration. J. Leukoc. Biol. 95, 265–274 (2014). [PMID: 24072879]
17. Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S. & Proost, P. Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands. Front. Immunol. 8, 1970 (2017). [PMID: 29379506]
18. Pearl, J. E., Saunders, B., Ehlers, S., Orme, I. M. & Cooper, A. M. Inflammation and lymphocyte activation during mycobacterial infection in the interferon-gamma-deficient mouse. Cell Immunol. 211, 43–50 (2001). [PMID: 11585387]
19. Swindle, E. J., Brown, J. M., Rådinger, M., DeLeo, F. R. & Metcalfe, D. D. Interferon-γ enhances both the anti-bacterial and the pro-inflammatory response of human mast cells to Staphylococcus aureus. Immunology 146, 470–485 (2015). [PMID: 26288256]
20. Lee, S. K. et al. Interferon-γ excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 37, 880–892 (2012). [PMID: 23159227]
21. Fang, D. et al. Transient T-bet expression functionally specifies a distinct T follicular helper subset. J. Exp. Med. 215, 2705–2714 (2018). [PMID: 30232200]
22. Jackson, S. W. et al. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J. Exp. Med. 213, 733–750 (2016). [PMID: 27069113]
23. Peng, S. L., Szabo, S. J. & Glimcher, L. H. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl Acad. Sci. USA 99, 5545–5550 (2002). [PMID: 11960012]
24. Canna, S. W. & Marsh, R. A. Pediatric hemophagocytic lymphohistiocytosis. Blood 135, 1332–1343 (2020). [PMID: 32107531]
25. Bhatt, N. S., Oshrine, B. & An Talano, J. Hemophagocytic lymphohistiocytosis in adults. Leuk. Lymphoma 60, 19–28 (2019). [PMID: 29966474]
26. Henter, J. I. et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48, 124–131 (2007). [PMID: 16937360]
27. Emile, J. F. et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127, 2672–2681 (2016). [PMID: 26966089]
28. Grom, A. A., Horne, A. & De Benedetti, F. Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 12, 259–268 (2016). [PMID: 27009539]
29. Bracaglia, C., Prencipe, G. & De Benedetti, F. Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr. Rheumatol. Online J. 15, 5 (2017). [PMID: 28095869]
30. Ravelli, A. et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann. Rheum. Dis. 75, 481–489 (2016). [PMID: 26865703]
31. Bergsten, E. et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130, 2728–2738 (2017). [PMID: 28935695]
32. Henter, J. I. et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 78, 2918–2922 (1991). [PMID: 1954380]
33. Imashuku, S. et al. Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Med. Pediatr. Oncol. 31, 131–137 (1998). [PMID: 9722893]
34. Schneider, E. M. et al. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 100, 2891–2898 (2002). [PMID: 12351400]
35. Billiau, A. D., Roskams, T., Van Damme-Lombaerts, R., Matthys, P. & Wouters, C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood 105, 1648–1651 (2005). [PMID: 15466922]
36. Xu, X. J. et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J. Pediatr. 160, 984–990.e1 (2012). [PMID: 22226576]
37. Prencipe, G. et al. The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis. PLoS ONE 14, e0226043 (2019). [PMID: 31846457]
38. Yang, S. L. et al. Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. Cytokine 85, 14–17 (2016). [PMID: 27269180]
39. Buatois, V. et al. Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis. Transl. Res. 180, 37–52.e2 (2017). [PMID: 27559680]
40. Bracaglia, C. et al. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 76, 166–172 (2017). [PMID: 27296321]
41. Jordan, M. B., Hildeman, D., Kappler, J. & Marrack, P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8 T cells and interferon gamma are essential for the disorder. Blood 104, 735–743 (2004). [PMID: 15069016]
42. Rood, J. E. et al. ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice. Blood 127, 426–435 (2016). [PMID: 26518437]
43. Kögl, T. et al. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood 121, 604–613 (2013). [PMID: 23190531]
44. Pachlopnik Schmid, J. et al. Neutralization of IFNγ defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol. Med. 1, 112–124 (2009). [PMID: 20049711]
45. Zoller, E. E. et al. Hemophagocytosis causes a consumptive anemia of inflammation. J. Exp. Med. 208, 1203–1214 (2011). [PMID: 21624938]
46. van Dommelen, S. L. et al. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity 25, 835–848 (2006). [PMID: 17088087]
47. Humblet-Baron, S. et al. IFN-γ and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis. J. Allergy Clin. Immunol. 143, 2215–2226.e7 (2019). [PMID: 30578871]
48. Burn, T. N. et al. Genetic deficiency of interferon-gamma reveals interferon-gamma-independent manifestations of murine hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 72, 335–347 (2020). [PMID: 31400073]
49. Tesi, B. et al. Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-gamma receptor deficiency. J. Allergy Clin. Immunol. 135, 1638–1641 (2015). [PMID: 25592983]
50. Behrens, E. M. et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J. Clin. Invest. 121, 2264–2277 (2011). [PMID: 21576823]
51. Weaver, L. K., Chu, N. & Behrens, E. M. Brief report: interferon-γ-mediated immunopathology potentiated by toll-like receptor 9 activation in a murine model of macrophage activation syndrome. Arthritis Rheumatol. 71, 161–168 (2019). [PMID: 30073799]
52. Brisse, E. et al. Mouse cytomegalovirus infection in BALB/c mice resembles virus-associated secondary hemophagocytic lymphohistiocytosis and shows a pathogenesis distinct from primary hemophagocytic lymphohistiocytosis. J. Immunol. 196, 3124–3134 (2016). [PMID: 26903481]
53. Brisse, E. et al. Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis. Virol. J. 14, 240 (2017). [PMID: 29258535]
54. de Benedetti, F. et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34, 1158–1163 (1991). [PMID: 1930333]
55. De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385–2395 (2012). [PMID: 23252525]
56. Strippoli, R. et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 64, 1680–1688 (2012). [PMID: 22108837]
57. Prencipe, G. et al. Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J. Allergy Clin. Immunol. 141, 1439–1449 (2018). [PMID: 28807602]
58. Weiss, E. S. et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood 131, 1442–1455 (2018). [PMID: 29326099]
59. Yasin, S. et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology 59, 361–366 (2020). [PMID: 31326996]
60. Girard-Guyonvarc’h, C. et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood 131, 1430–1441 (2018). [PMID: 29295842]
61. Tsoukas, P. et al. Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induced hyperinflammation. Blood 136, 2162–2174 (2020). [PMID: 32589707]
62. Canna, S. W. et al. Proceedings from the 2 next gen therapies for systemic juvenile idiopathic arthritis and macrophage activation syndrome symposium held on October 3–4, 2019. Pediatr. Rheumatol. Online J. 18, 53 (2020). [PMID: 32664935]
63. Schulert, G. S. et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 71, 1943–1954 (2019). [PMID: 31379071]
64. Saper, V. E. et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann. Rheum. Dis. 78, 1722–1731 (2019). [PMID: 31562126]
65. Iriguchi, S. et al. T-cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of macrophages in the lung. Blood 125, 370–382 (2015). [PMID: 25349175]
66. Gao, D. K. et al. IFN-γ is essential for alveolar macrophage driven pulmonary inflammation in macrophage activation syndrome. JCI Insight 6, 147593 (2021). [PMID: 34314387]
67. Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018). [PMID: 28925994]
68. Teachey, D. T. et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154–5157 (2013). [PMID: 23678006]
69. Brady, J. L. et al. Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model. Clin. Transl. Immunol. 3, e29 (2014). [DOI: 10.1038/cti.2014.28]
70. Oved, J. H., Barrett, D. M. & Teachey, D. T. Cellular therapy: immune-related complications. Immunol. Rev. 290, 114–126 (2019). [PMID: 31355491]
71. Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664–679 (2016). [PMID: 27076371]
72. Wouters, C. H., Maes, A., Foley, K. P., Bertin, J. & Rose, C. D. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr. Rheumatol. Online J. 12, 33 (2014). [PMID: 25136265]
73. Takada, S. et al. Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages. J. Allergy Clin. Immunol. 141, 339–349.e11 (2018). [PMID: 28587749]
74. Rosenzweig, H. L. et al. Nucleotide oligomerization domain-2 (NOD2)-induced uveitis: dependence on IFN-gamma. Invest. Ophthalmol. Vis. Sci. 50, 1739–1745 (2009). [PMID: 19098321]
75. Janssen, C. E. et al. Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. J. Allergy Clin. Immunol. 129, 1076–1084 (2012). [PMID: 22464675]
76. Sarens, I. L. et al. Blau syndrome-associated uveitis: preliminary results from an international prospective interventional case series. Am. J. Ophthalmol. 187, 158–166 (2018). [PMID: 28887115]
77. Seery, J. P. et al. A central role for alpha beta T cells in the pathogenesis of murine lupus. J. Immunol. 162, 7241–7248 (1999). [PMID: 10358171]
78. Enghard, P., Langnickel, D. & Riemekasten, G. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis. Scand. J. Rheumatol. 35, 209–216 (2006). [PMID: 16766368]
79. Jacob, C. O., van der Meide, P. H. & McDevitt, H. O. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J. Exp. Med. 166, 798–803 (1987). [PMID: 3114409]
80. Ozmen, L. et al. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25, 6–12 (1995). [PMID: 7843255]
81. Haas, C. & Ryffel, B. & Le Hir, M. IFN-γ receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB × NZW)F1 mice. J. Immunol. 160, 3713–3718 (1998). [PMID: 9558072]
82. Balomenos, D., Rumold, R. & Theofilopoulos, A. N. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101, 364–371 (1998). [PMID: 9435308]
83. Domeier, P. P. et al. IFN-γ receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J. Exp. Med. 213, 715–732 (2016). [PMID: 27069112]
84. Rana, A. et al. Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 21, 1105–1112 (2012). [PMID: 22759859]
85. Lyn-Cook, B. D. et al. Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol. Immunol. 61, 38–43 (2014). [PMID: 24865418]
86. Kokic, V. et al. Relationship between vitamin D, IFN-γ, and E2 levels in systemic lupus erythematosus. Lupus 25, 282–288 (2016). [PMID: 26405019]
87. Munroe, M. E. et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75, 2014–2021 (2016). [PMID: 27088255]
88. Chiche, L., Jourde-Chiche, N., Pascual, V. & Chaussabel, D. Current perspectives on systems immunology approaches to rheumatic diseases. Arthritis Rheum. 65, 1407–1417 (2013). [PMID: 23450649]
89. Zhu, J., Huang, X. & Yang, Y. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther. 16, 1300–1307 (2008). [PMID: 18443600]
90. Fava, A. et al. Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis. JCI Insight 5, e138345 (2020). [>PMCID: ]
91. Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211–221 (2020). [PMID: 31851795]
92. Furie, R. A. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, e208–e219 (2019). [DOI: 10.1016/S2665-9913(19)30076-1]
93. Lortat-Jacob, H., Baltzer, F. & Grimaud, J. A. Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. J. Biol. Chem. 271, 16139–16143 (1996). [PMID: 8663206]
94. Rutenfranz, I. & Kirchner, H. Pharmacokinetics of recombinant murine interferon-gamma in mice. J. Interferon Res. 8, 573–580 (1988). [PMID: 3148668]
95. Pascarella, A. et al. Monocytes from patients with macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis are hyperresponsive to interferon gamma. Front. Immunol. 12, 801 (2021). [DOI: 10.3389/fimmu.2021.663329]
96. Hu, X., Li, W. P., Meng, C. & Ivashkiv, L. B. Inhibition of IFN-γ signaling by glucocorticoids. J. Immunol. 170, 4833–4839 (2003). [PMID: 12707366]
97. Ibarra, M. F. et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin. Vaccin. Immunol. 18, 609–614 (2011). [DOI: 10.1128/CVI.00306-10]
98. Wada, T. et al. Cytokine profiles in children with primary Epstein-Barr virus infection. Pediatr. Blood Cancer 60, E46–E48 (2013). [PMID: 23382108]
99. Shimizu, M. et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology 49, 1645–1653 (2010). [PMID: 20472718]
100. Mizuta, M. et al. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children. Rheumatology https://doi.org/10.1093/rheumatology/keaa299 (2020). [DOI: 10.1093/rheumatology/keaa299]
101. de Matteis, A. et al. Traditional laboratory parameters and new biomarkers in macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 72 (suppl 4). https://acrabstracts.org/abstract/traditional-laboratory-parameters-and-new-biomarkers-in-macrophage-activation-syndrome-and-secondary-hemophagocytic-lymphohistiocytosis/ (2020).
102. Lim, K. L., Jones, A. C., Brown, N. S. & Powell, R. J. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products. Ann. Rheum. Dis. 52, 429–435 (1993). [PMID: 8323394]
103. Whyte, M. P. et al. Unique variant of NOD2 pediatric granulomatous arthritis with severe 1,25-dihydroxyvitamin D-mediated hypercalcemia and generalized osteosclerosis. J. Bone Min. Res. 33, 2071–2080 (2018). [DOI: 10.1002/jbmr.3532]
104. Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207–215 (2011). [PMID: 21221121]
105. Mizuta, M., Shimizu, M., Inoue, N., Nakagishi, Y. & Yachie, A. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome. Cytokine 119, 182–187 (2019). [PMID: 30952065]
106. My, L. T. et al. Comprehensive analyses and characterization of haemophagocytic lymphohistiocytosis in Vietnamese children. Br. J. Haematol. 148, 301–310 (2010). [PMID: 19863536]
107. Takada, H. et al. Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin. Exp. Immunol. 133, 448–453 (2003). [PMID: 12930373]
108. Han, J. H. et al. Elevated circulating levels of the interferon-γ-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still’s disease. Sci. Rep. 7, 46652 (2017). [PMID: 28436448]
109. Takakura, M. et al. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Clin. Immunol. 208, 108252 (2019). [PMID: 31449879]
110. Schulert, G. S. et al. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome. Ann. Rheum. Dis. 80, 617–625 (2021). [PMID: 33277241]
111. Carvalheiro, T. et al. Tolerogenic versus inflammatory activity of peripheral blood monocytes and dendritic cells subpopulations in systemic lupus erythematosus. Clin. Dev. Immunol. 2012, 934161 (2012). [PMID: 22969819]
112. Ferreira, G. A., Teixeira, A. L. & Sato, E. I. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 19, 927–934 (2010). [PMID: 20410153]
113. Locatelli, F. et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N. Engl. J. Med. 382, 1811–1822 (2020). [PMID: 32374962]
114. Lounder, D. T., Bin, Q., de Min, C. & Jordan, M. B. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 3, 47–50 (2019). [PMID: 30617216]
115. Bracaglia, C. et al. IFNg neutralization in patients with NRLC4- and CDC42-associated autoinflammatory disease characterized by recurrent and severe HLH. Pediatr. Blood Cancer 67 (Suppl 1), e28077 (2019).
116. Lam, M. T. et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J. Exp. Med. 216, 2778–2799 (2019). [PMID: 31601675]
117. De Benedetti, F. et al. Emapalumab (anti-interferon-gamma monoclonal antibody) in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA). Ann. Rheum. Dis. 79, 180 (2020). [DOI: 10.1136/annrheumdis-2020-eular.3169]
118. Gabr, J. B. et al. Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still’s disease: case report and review of the literature. Ann. Transl. Med. 8, 887 (2020). [PMID: 32793731]
119. Boedigheimer, M. J. et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci. Med. 4, e000226 (2017). [PMID: 29018537]
120. Chen, P. et al. Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm. Res. 32, 640–653 (2015). [PMID: 25213774]
121. Bozza, S. et al. Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 108, 3387–3396 (2006). [PMID: 16840729]
122. Presti, R. M., Pollock, J. L., Dal Canto, A. J., O’Guin, A. K. & Virgin, H. W. T. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J. Exp. Med. 188, 577–588 (1998). [PMID: 9687534]
123. Bao, S., Beagley, K. W., France, M. P., Shen, J. & Husband, A. J. Interferon-gamma plays a critical role in intestinal immunity against Salmonella typhimurium infection. Immunology 99, 464–472 (2000). [PMID: 10712678]
124. Fidan, I., Yesilyurt, E., Gurelik, F. C., Erdal, B. & Imir, T. Effects of recombinant interferon-gamma on cytokine secretion from monocyte-derived macrophages infected with Salmonella typhi. Comp. Immunol. Microbiol. Infect. Dis. 31, 467–475 (2008). [PMID: 17904635]
125. Salat, J., Jelinek, J., Chmelar, J. & Kopecky, J. Efficacy of gamma interferon and specific antibody for treatment of microsporidiosis caused by Encephalitozoon cuniculi in SCID mice. Antimicrob. Agents Chemother. 52, 2169–2174 (2008). [PMID: 18347109]
126. Sumaria, N. et al. The roles of interferon-gamma and perforin in antiviral immunity in mice that differ in genetically determined NK-cell-mediated antiviral activity. Immunol. Cell Biol. 87, 559–566 (2009). [PMID: 19564888]
127. Dorman, S. E. et al. Viral infections in interferon-gamma receptor deficiency. J. Pediatr. 135, 640–643 (1999). [PMID: 10547254]
128. Tran, D. Q. Susceptibility to mycobacterial infections due to interferon-gamma and interleukin-12 pathway defects. Allergy Asthma Proc. 26, 418–421 (2005). [PMID: 16450579]
129. Kampmann, B. et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J. Clin. Invest. 115, 2480–2488 (2005). [PMID: 16127458]
130. Wongkulab, P., Wipasa, J., Chaiwarith, R. & Supparatpinyo, K. Autoantibody to interferon-gamma associated with adult-onset immunodeficiency in non-HIV individuals in Northern Thailand. PLoS ONE 8, e76371 (2013). [PMID: 24086734]
131. Sologuren, I. et al. Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum. Mol. Genet. 20, 1509–1523 (2011). [PMID: 21266457]
132. Lammas, D. A., Casanova, J. L. & Kumararatne, D. S. Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway. Clin. Exp. Immunol. 121, 417–425 (2000). [PMID: 10971505]
133. Doffinger, R. et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38, e10–e14 (2004). [PMID: 14679469]
134. Poulin, S. et al. Fatal Mycobacterium colombiense/cytomegalovirus coinfection associated with acquired immunodeficiency due to autoantibodies against interferon gamma: a case report. BMC Infect. Dis. 13, 24 (2013). [PMID: 23336346]
135. Hommes, D. W. et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut 55, 1131–1137 (2006). [PMID: 16507585]
136. Reinisch, W. et al. Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis. 16, 233–242 (2010). [PMID: 19637334]
137. US Food and Drug Administration. Center for Drug Evaluation Research. BLA Multi-Disciplinary Review and Evaluation. BLA 761107. GAMIFANT(emapalumab), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761107Orig1s000MultidisciplineR.pdf (2018).
138. Tucci, F. et al. Treatment with emapalumab in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated BCGitis. Haematologica 106, 641–646 (2021). [PMID: 32817285]
139. Put, K. et al. Inflammatory gene expression profile and defective interferon-gamma and granzyme K in natural killer cells from systemic juvenile idiopathic arthritis patients. Arthritis Rheumatol. 69, 213–224 (2017). [PMID: 27696741]
140. Reinisch, W. et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease. Gut 55, 1138–1144 (2006). [PMID: 16492717]
141. Werth, V. P. et al. Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 69, 1028–1034 (2017). [PMID: 28118537]

MeSH Term

Chemicals